Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants

NCT ID: NCT02437721

Last Updated: 2018-08-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to show equivalence of an infant formula containing L-5- Methyltetrahydrofolate (MTHF) compared to a standard infant formula containing folic acid in respect to weight gain of healthy term infants receiving these infant formulae exclusively during the first 4 months of life. Healthy non breast fed infants will be randomized to receive either a standard infant formula with folic acid or a corresponding formula with MTHF instead of folic acid. Besides weight and length further anthropometric measures will be taken monthly from the age of 4 weeks to the age of 16 weeks and at the age 4 and 16 weeks blood samples will be taken for the determination of folate status and genotyping. As a reference the same measures will be taken in a group of breast fed infants, whose mothers' folate status will be determined as well.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth and Development

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

infant formula containing folic acid

Infant formula including folic acid within the range stipulated by European legislation on infant formula

Group Type ACTIVE_COMPARATOR

infant formula containing folic acid

Intervention Type OTHER

infant formula containing MTHF

Infant formula including MTHF instead of folic acid

Group Type EXPERIMENTAL

infant formula containing MTHF

Intervention Type OTHER

Breast milk

non randomized reference group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

infant formula containing folic acid

Intervention Type OTHER

infant formula containing MTHF

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

folic acid L-5-Methyltetrahydrofolate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent (by parents, caregiver)
* Healthy male or female infants \<28 days of life
* Gestational age at delivery ≥37 and ≤42 weeks
* Birth weight between 2500 - 4500g
* Parents / Caregivers are able to speak Serbian language

Exclusion Criteria

* Serious acquired or congenital diseases that is expected to interfere with normal feeding or growth
* Feeding of more than 10% of energy (1 bottle/day) from sources other than the formula (or breast milk in the reference group) at inclusion
* Participation in another clinical study
* Mothers with diabetes mellitus (including gestational diabetes)
* Reason to presume that the parents are unable to meet the study plan requirements
* Diseases of the mother which have an effect on the child's gastro-intestinal tract/ability to be fed
* Major abnormalities in hematological parameters
* Major abnormalities in hepatic, renal or metabolic functions
* Use of medication and vitamin supplements except vitamin K or D supplementation or vaccination
* Mother follows a vegan diet
Minimum Eligible Age

1 Day

Maximum Eligible Age

27 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Clinic Dr Dragisa Misovic-Dedinje

OTHER

Sponsor Role collaborator

HiPP GmbH & Co. Vertrieb KG

INDUSTRY

Sponsor Role collaborator

Institute for Laboratory Diagnostics Konzilijum

UNKNOWN

Sponsor Role collaborator

Bevital AS

UNKNOWN

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

Sermon CRO

INDUSTRY

Sponsor Role collaborator

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role collaborator

DSM Nutritional Products, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Berthold Koletzko, Prof.

Role: PRINCIPAL_INVESTIGATOR

Ludwig-Maximilians - University of Munich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KBC Dr Dragiša Mišović-Dedinje

Belgrade, , Serbia

Site Status

HiPP Clinical Study Center

Belgrade, , Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Serbia

References

Explore related publications, articles, or registry entries linked to this study.

Obeid R, Warnke I, Wittke A, Bendik I, Troesch B, Schoop R, Hecht C, Demmelmair J, Koletzko B; MEFOLIN Study Group. Infant blood concentrations of folate markers and catabolites are modified by 5,10-methylenetetrahydrofolate reductase C677T genotype and dietary folate source. Am J Clin Nutr. 2023 Mar;117(3):509-517. doi: 10.1016/j.ajcnut.2022.09.002.

Reference Type DERIVED
PMID: 36872017 (View on PubMed)

Troesch B, Demmelmair J, Gimpfl M, Hecht C, Lakovic G, Roehle R, Sipka L, Trisic B, Vusurovic M, Schoop R, Zdjelar S, Koletzko B; MEFOLIN Study Group. Suitability and safety of L-5-methyltetrahydrofolate as a folate source in infant formula: A randomized-controlled trial. PLoS One. 2019 Aug 19;14(8):e0216790. doi: 10.1371/journal.pone.0216790. eCollection 2019.

Reference Type DERIVED
PMID: 31425504 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-05-06-MTHF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preterm Infants Fed a Human Milk Fortifier
NCT05551975 NOT_YET_RECRUITING NA